BioTime Inc (NYSE:BTX) shares are on the rise following the publication of positive preclinical results from its HyStem cell and drug delivery platform.
The results show that the delivery technology may alleviate ischemic brain injury and restore function by reducing neuroinflammation.
Shares of BioTime were up nearly 6% to $1.51 in Tuesday afternoon trading.
Ischemia occurs when there is insufficient blood flow to an organ. It can be difficult to administer drugs to a brain that has been affected by an ischemic stroke due to the blood-brain barrier.
“Results from this study, designed to simulate the clinical needs of human stroke, underscore the ability of our proprietary HyStem delivery technology to target therapy dosing to a specific anatomical site such as to the ischemic core, and minimize dissipation to surrounding tissues,” said Senior Vice President and Global Head of Product Development Francois Binette in the company’s press release.
The clinical-stage biotech focuses on the development and commercialization of novel therapies for the treatment of degenerative diseases.
Contact Lenore Fedow at [email protected]